CN104784166A - 抗病毒化合物、包含该化合物的剂型及其用途 - Google Patents

抗病毒化合物、包含该化合物的剂型及其用途 Download PDF

Info

Publication number
CN104784166A
CN104784166A CN201510115375.7A CN201510115375A CN104784166A CN 104784166 A CN104784166 A CN 104784166A CN 201510115375 A CN201510115375 A CN 201510115375A CN 104784166 A CN104784166 A CN 104784166A
Authority
CN
China
Prior art keywords
compound
virus
formula
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201510115375.7A
Other languages
English (en)
Chinese (zh)
Inventor
Y.S.巴布
P.钱德
S.班蒂亚
S.阿诺
J.M.基尔佩特里克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biocryst Pharmaceuticals Inc
Original Assignee
Biocryst Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38169715&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104784166(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/US2006/013535 external-priority patent/WO2007117241A1/en
Application filed by Biocryst Pharmaceuticals Inc filed Critical Biocryst Pharmaceuticals Inc
Priority claimed from CNA200780013022XA external-priority patent/CN101420948A/zh
Publication of CN104784166A publication Critical patent/CN104784166A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201510115375.7A 2006-02-13 2007-02-12 抗病毒化合物、包含该化合物的剂型及其用途 Pending CN104784166A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US77274806P 2006-02-13 2006-02-13
US60/772748 2006-02-13
USPCT/US2006/013535 2006-04-12
PCT/US2006/013535 WO2007117241A1 (en) 2006-04-12 2006-04-12 Intramuscular antiviral treatments
CNA200780013022XA CN101420948A (zh) 2006-02-13 2007-02-12 静脉内抗病毒治疗

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNA200780013022XA Division CN101420948A (zh) 2006-02-13 2007-02-12 静脉内抗病毒治疗

Publications (1)

Publication Number Publication Date
CN104784166A true CN104784166A (zh) 2015-07-22

Family

ID=38169715

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510115375.7A Pending CN104784166A (zh) 2006-02-13 2007-02-12 抗病毒化合物、包含该化合物的剂型及其用途

Country Status (12)

Country Link
EP (1) EP1986626A1 (enExample)
JP (3) JP2009538822A (enExample)
KR (9) KR102475176B1 (enExample)
CN (1) CN104784166A (enExample)
AU (1) AU2007215156A1 (enExample)
BR (1) BRPI0707769A2 (enExample)
CA (1) CA2642260C (enExample)
EA (1) EA025483B1 (enExample)
HK (1) HK1212250A1 (enExample)
MX (2) MX393640B (enExample)
MY (1) MY166063A (enExample)
WO (1) WO2007095218A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0707769A2 (pt) * 2006-02-13 2011-05-10 Biocryst Pharm Inc tratamentos antivirais intravenosos
CN101367750B (zh) * 2007-08-14 2012-05-23 中国人民解放军军事医学科学院毒物药物研究所 (1s,2s,3s,4r)-3-[(1s)-1-乙酰氨-2-乙基-丁基]-4-胍基-2-羟基-环戊基-1-羧酸水合物及其医药用途
KR20220033561A (ko) 2020-09-07 2022-03-17 주식회사 경보제약 페라미비르 화합물을 포함하는 프리믹스 제형의 제약학적 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001097792A2 (en) * 2000-06-22 2001-12-27 Glaxosmithkline K K Neuraminidase inhibitors in the treatment of equine influenza virus infection

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ412898A3 (cs) * 1996-06-14 1999-08-11 Biocryst Pharmaceuticals, Inc. Substituované cyklopentanové sloučeniny, použitelné jako inhibitory neuraminidázy
PT1040094E (pt) * 1997-12-17 2009-06-03 Biocryst Pharm Inc Compostos de ciclopentano e de ciclopenteno substituídos úteis como inibidores da neuraminidase
BRPI0707769A2 (pt) * 2006-02-13 2011-05-10 Biocryst Pharm Inc tratamentos antivirais intravenosos

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001097792A2 (en) * 2000-06-22 2001-12-27 Glaxosmithkline K K Neuraminidase inhibitors in the treatment of equine influenza virus infection

Also Published As

Publication number Publication date
MX2020002008A (es) 2020-07-13
KR20190072681A (ko) 2019-06-25
KR20230003248A (ko) 2023-01-05
KR20200143519A (ko) 2020-12-23
KR102475176B1 (ko) 2022-12-07
EP1986626A1 (en) 2008-11-05
CA2642260C (en) 2016-08-09
JP2013256527A (ja) 2013-12-26
EA200870263A1 (ru) 2009-06-30
KR20180024027A (ko) 2018-03-07
KR101992585B9 (ko) 2022-09-20
JP6073202B2 (ja) 2017-02-01
MX393640B (es) 2025-03-21
JP2009538822A (ja) 2009-11-12
KR20140132778A (ko) 2014-11-18
CA2642260A1 (en) 2007-08-23
KR102323339B1 (ko) 2021-11-08
KR20160129105A (ko) 2016-11-08
HK1212250A1 (en) 2016-06-10
KR101992585B1 (ko) 2019-06-25
MY166063A (en) 2018-05-23
WO2007095218A1 (en) 2007-08-23
KR20080096829A (ko) 2008-11-03
KR20210135632A (ko) 2021-11-15
EA025483B1 (ru) 2016-12-30
JP2015180695A (ja) 2015-10-15
KR20210076189A (ko) 2021-06-23
KR102194015B1 (ko) 2020-12-22
AU2007215156A1 (en) 2007-08-23
BRPI0707769A2 (pt) 2011-05-10
KR102267754B1 (ko) 2021-06-23
MX2008010394A (es) 2009-01-12

Similar Documents

Publication Publication Date Title
JP2024528418A5 (enExample)
US12121503B2 (en) Antiviral treatments
HK1212250A1 (en) Antiviral compounds, unit dosage form comprising said compounds and use thereof
BR112012011261A2 (en) treatment of microbial infections
AU2016262644B2 (en) Intravenous antiviral treatments
JP2009538822A5 (enExample)
NZ570538A (en) Intravenous antiviral treatments
JP2009533428A (ja) 筋肉内抗ウイルス処置
CN104244943A (zh) 预防和治疗病毒感染的材料与方法
KR20080113099A (ko) 근육내 항바이러스 치료

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1212250

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20150722

RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1212250

Country of ref document: HK